Trials for Cervical-Cancer Detection Device

(Norcross, GA, USA), the developer of the device.

The grant will be used for the clinical trial of the technology at Grady Memorial Hospital (Atlanta, GA, USA) under the guidance of Dr. Lisa Flowers of Emory University. The noninvasive cervical-cancer detection device uses proprietary technology to identify cancers and precancers painlessly and noninvasively by analyzing light reflected from the cervix. The device creates an image of the cervix that highlights the location and severity of disease. The technology distinguishes between normal and diseased tissue by detecting biochemical and morphologic changes at the cellular level. Unlike Pap tests, this test does require a tissue sample or laboratory analysis, and results are instantly available.

A pre-pivotal clinical study, sponsored by the U.S. National Cancer Institute, indicated that the test could reduce by 55% the number of unnecessary follow-up procedures as a result of false-positive Pap results, with huge cost savings to the healthcare system. Cervical cancer is the third most common cancer among women.

"This new technology offers the potential to overcome many of the barriers to early detection of cervical cancer that exist today,” said Dr. Flowers. "It could eliminate the anxiety of waiting for days for test results and many of the false-positive results that are a burden on the patient and the healthcare system.”




Related Links:
SpectRx